Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company focused on growth and innovation, has announced the signing of an exclusive Manufacturing and Supply Agreement with a leading Canadian diversified healthcare services provider. This agreement entails supplying various sanitary products, including hand sanitizer, hand soap, and hand lotions, to be distributed through a network of publicly funded healthcare organizations represented by a buying group.
“We are honored to be chosen by our Client, a prominent figure in the Canadian pharmaceutical sector, as their exclusive supplier for this extensive project spanning multiple years and jurisdictions. We anticipate this partnership will lay a solid foundation for future collaborations.”
The initial term of the Agreement is five years, with a three-year renewal option available to the Buying Group. While there are no minimum order quantities specified, the anticipated volumes suggest potential annual revenues under the Agreement could reach up to $6.0 million by the end of the initial term. Crescita’s revenue from manufacturing will hinge on the Client’s success in transitioning Buying Group Members to their new sanitizer dispensing solution. As the exclusive manufacturing partner, Crescita will support the Client in expanding the market for these Products within the public sector healthcare through competitive bidding processes with other buying groups across Canada.
Serge Verreault, President and CEO of Crescita, remarked, “We are very pleased to have been selected by our Client, a key player in the Canadian pharmaceutical industry, as their exclusive supplier for this multi-year initiative covering multiple jurisdictions. We believe this strong partnership will pave the way for future collaborations.”
About Crescita Therapeutics Inc. Crescita (TSX: CTX and OTC US: CRRTF) is a Canadian commercial dermatology company known for its focus on growth and innovation, supported by robust in-house R&D and manufacturing capabilities. The company offers a range of high-quality, science-based non-prescription skincare products and is advancing prescription products from early to commercial stages. Crescita also owns several proprietary transdermal delivery platforms designed to enhance the delivery of active ingredients into or through the skin.
